Biotech firm Windtree Therapeutics announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its all-time high of $808. Based in Warrington, Pennsylvania, and listed on Nasdaq as WINT, Windtree is raising $520 million to facilitate these acquisitions, building on an earlier commitment of $200 million. The company will collaborate with crypto exchange Kraken for asset custody. This investment strategy is part of a broader trend where publicly traded companies diversify their portfolios by investing in cryptocurrencies beyond Bitcoin. Despite a recent dip in its stock by 5%, Windtree's share price has surged 162% over the past month, echoing similar moves by firms like Nano Labs, which announced a $1 billion BNB purchase this week. Windtree's CEO emphasized the importance of securing funds for BNB purchases pending stockholder approval, marking a significant shift in traditional business models towards incorporating digital assets on corporate balance sheets.

Source đź”—